New Huntington's drug enters first human tests

NCT ID NCT07246941

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This early-stage study tests a new drug called RG6496 in people who carry the gene for Huntington's disease. The main goal is to check if the drug is safe and how the body handles it. About 40 participants will receive a single dose injected into the spine, with some getting a placebo. The study has two parts: an initial blinded phase and an open-label extension where everyone gets the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUNTINGTON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Huntington disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cambridge Centre for Brain Repair

    RECRUITING

    Cambridge, Cambridgeshire, CB2 0PY, United Kingdom

  • Hospital Britanico de Buenos Aires

    RECRUITING

    Ciudad Autonoma Bs As, C1280AEB, Argentina

  • Monash Health

    SUSPENDED

    Clayton, Victoria, 3168, Australia

  • New Zealand Brain Research Institute

    RECRUITING

    Christchurch, 8011, New Zealand

  • Royal Melbourne Hospital

    RECRUITING

    Parkville, Victoria, 3050, Australia

  • Westmead Hospital

    RECRUITING

    Westmead, New South Wales, 2145, Australia